Now Available On Demand: Cell & Gene Day, 2024
Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise — but the business models to support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? Find out at Cell & Gene Day 2024, a free virtual event, WATCH ON DEMAND HERE.
Conference: Meeting on the Med, 2024
Precision will be at this year’s Meeting on the Med, April 9-11, 2023, in Rome, Italy. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
- Visit us through any of the numerous networking opportunities at Meeting on the Med 24′
- Be sure to attend the Precision sponsored workshop on April 9, 2024, at 5:15 PM CET |Location: Rome Cavalieri, A Waldorf Astoria Hotel
You can register for Meeting on the Med below:
Conference: Gene Therapy for Rare Disorders (GTRD), 2024
Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
- Precision will have a plenary speaking position on March 27, 2024, 8:30 – 9:00 am.
- Precision’s Andy Kinley (VP, Innovation & Clinical Science, Precision for Medicine) will Chair the Clinical track session, “Clinical Endpoints for Rare Disease Studies,” on March 28, 2024, 11:15 am – 12:15 pm.
Connect with our Advanced Therapy experts
- Schedule in-person or virtual meetings with our team
—
Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET
- Key Takeaways
- Market trends and expectations for Gene Therapies & Rare Diseases in 2024
- Predictions on Potential Approvals in 2024
- Innovative Trends & Technologies
- Evolution of CMC and manufacturing
Speakers:
- [Moderator] Jake Greenwood, VP, Project Farma
- Faraz Ali, CEO, Tenaya Therapeutics
- Debs Phippard, CSO, Precision for Medicine
- Frank Bugg, Global Head of BaseCamp Operations & Commercial, ElevateBio
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET
- Andy Kinley, VP, Innovation & Clinical Science (Precision for Medicine) to Chair
Simon Fleming Joins Precision
Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.
Article: Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply
Precision’s Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series.
“Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types.” (subscription required):